GlassScriptPhysician profile
Roshanak Habibi
NPI 1639559032
$6,813.39
in general payments reported to CMS, 2019-2025
27 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $295 · 2023: $1,167 · 2024: $3,547 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,345 · Travel and Lodging: $1,131 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,344.78 |
| Travel and Lodging | $1,131.35 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,916.17 | 2023-2025 | Minimed 780g |
| Abbott Laboratories | $875.89 | 2022-2025 | Freestyle Libre 3 |
| Insulet Corporation | $576.09 | 2023-2025 | Omnipod |
| Corcept Therapeutics | $563.79 | 2024-2025 | Korlym |
| Amgen INC. | $479.79 | 2024-2025 | Repatha, Evenity, Tavneos |
| Dexcom, INC. | $435.55 | 2023-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $363.96 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Kyowa Kirin, INC. | $282.24 | 2024-2025 | Crysvita |
| Sanofi-Aventis U.S. LLC | $212.47 | 2024-2025 | |
| Cequr Corporation | $194.07 | 2024 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.55 | 2024 | Jardiance |
| Lilly USA, LLC | $127.52 | 2022-2025 | Mounjaro, Zepbound |
| Beta Bionics, INC. | $105.66 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $90.37 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $81.06 | 2025 | Yorvipath |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $76.98 | 2024-2025 | |
| Almatica Pharma LLC | $60.05 | 2024-2025 | Teriparatide |
| Madrigal Pharmaceuticals | $52.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Amneal Pharmaceuticals LLC | $29.64 | 2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $27.29 | 2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $24.96 | 2025 | Recorlev |
| Recordati_rare_diseases_inc. | $23.86 | 2025 | Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $17.44 | 2024 | |
| Sequel Med Tech, LLC | $16.50 | 2025 | Twiist |
| Amphastar Pharmaceuticals, INC. | $15.72 | 2025 | |
| Abbvie INC. | $14.83 | 2024 | |
| Ibsa Pharma INC. | $13.21 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshanak Habibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.